Insulin lispro
Also known as: Humalog · Liprolog · Lyumjev (previously Liumjev) · Insulin lispro Sanofi · Bysumlog · ADMELOG · Humalog KwikPen · Humalog Mix50/50 KwikPen · Humalog Mix75/25 · Humalog Mix75/25 KwikPen
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, insulin lispro under the product names Humalog and Liprolog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis, as well as for the initial stabilisation of diabetes mellitus. Under the product name Lyumjev, it is indicated in the European Union for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. In the United States, insulin lispro under the product name ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
From: Source: European Medicines Agency (EMA), Humalog — EPAR, 13/07/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Liprolog — EPAR, 21/01/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Lyumjev (previously Liumjev) — EPAR, 13/07/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 86009 insulin lispro
- EMA
- EMEA/H/C/000088, EMEA/H/C/000393, EMEA/H/C/005037, EMEA/H/C/004303, EMEA/H/C/006158
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) ADMELOG
1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )
Data provided by the U.S. Food and Drug Administration.
Document date: 20260903 · Official document →
EMA (EU) Humalog
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.
Source: European Medicines Agency (EMA), Humalog — EPAR, 13/07/2026. © European Medicines Agency.
Document date: 13/07/2026 · Official document →
EMA (EU) Liprolog
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.
Source: European Medicines Agency (EMA), Liprolog — EPAR, 21/01/2026. © European Medicines Agency.
Document date: 21/01/2026 · Official document →
EMA (EU) Lyumjev (previously Liumjev)
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Source: European Medicines Agency (EMA), Lyumjev (previously Liumjev) — EPAR, 13/07/2026. © European Medicines Agency.
Document date: 13/07/2026 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Insulin lispro approved for in the European Union?
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus. (Source: European Medicines Agency (EMA), Humalog — EPAR, 13/07/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Humalog — EPAR, 13/07/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Liprolog — EPAR, 21/01/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Lyumjev (previously Liumjev) — EPAR, 13/07/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.